



| Press Release |

Recobia Therapeutics secures PSCC BOOST Grant in support of its mission to transform ADC administration.

Strasbourg, France – June 2nd, 2026 – Recobia Therapeutics today announced its selection as one of ten laureates of the BOOST Grant initiative by the Paris Saclay Cancer Cluster (PSCC).

ADCs are among the most potent targeted cancer therapies available today, yet all approved agents require intravenous infusion. The hydrogel delivery platform, RecoGel, developed by Recobia Therapeutics, is designed to address the formulation and delivery challenges that have so far prevented SC administration of these complex biologics, with the goal of replacing a hospital-based infusion with a simpler, faster subcutaneous injection without compromising efficacy.

The PSCC BOOST Grant is a pilot funding programme supporting innovative oncology projects at a critical development stage, with awards ranging from €120,000 to €250,000 per project.

For Recobia, the funded milestone is the pre-clinical validation on a minipig model, a species whose skin anatomy and SC tissue physiology closely mirror those of humans, using injection volumes consistent with the intended clinical target. This study will directly support the preclinical package required for a first-in-human application. *"This grant will allow us to validate RecoGel in clinically relevant conditions and strengthen our position with both pharma partners and investors,"* said Alexandre Detappe, co-founder and CSO of Recobia Therapeutics.

About Recobia Therapeutics

Recobia Therapeutics has been founded in 2022 in collaboration with ICANS, now Institut Strauss, as a preclinical-stage biotechnology-based start-up in Strasbourg. The company is pioneering a patented delivery platform for subcutaneous administration of high-dose monoclonal antibodies and antibody drug conjugates in oncology and hematology. Recobia Therapeutics wants to facilitate treatment access for oncology patients by transitioning biotherapies from intravenous to subcutaneous administration. The company has received support from SEMIA, Quest for Health and Paris Saclay Cancer Cluster (PSCC) and secured financing from the Grand Est Region, Bpifrance and Agence National de la Recherche (ANR).